


# How Maine Residents Are Impacted By High Rx Costs



**162,474**

**Maine Residents**

have been diagnosed with cancer.<sup>1</sup>



**130,128**

**Maine Residents**

have pre-diabetes or diabetes.<sup>1</sup>



**50,795**

**Maine Residents**

have heart disease.<sup>1</sup>

Between 2012 and 2017, the price of these name brand drugs increased:

**Revlimid**

treats forms of cancer

from \$147,413/yr

to \$247,496/yr<sup>2</sup>



**Lantus**

treats diabetes

from \$2,907/yr

to \$4,702/yr<sup>2</sup>



**Aggrenox**

treats heart disease

from \$3,030/yr

to \$5,930/yr<sup>2</sup>



**Rx 31%**

In 2017, 31% of Maine Residents stopped taking medication as prescribed due to cost.<sup>3</sup>

## Sources:

<sup>1</sup> Total does not include skin cancer. Source: AARP Public Policy Institute analysis using 2017 data from the Behavioral Risk Factor Surveillance System.

<sup>2</sup> Stephen W. Schondelmeyer and Leigh Purvis. Rx Price Watch Reports. Washington, DC: AARP Public Policy Institute, June 2019, <https://doi.org/10.26419/ppi.00073.000>.

<sup>3</sup> Among 19-64 year old population. State Health Access Data Assistance Center (SHADAC) analysis of National Health Interview Survey data, State Health Compare, SHADAC, University of Minnesota, [statehealthcompare.shadac.org](http://statehealthcompare.shadac.org), Accessed September 5, 2019